In a message dated 4/17/2013 12:26:19 P.M. Central Daylight Time,  
[email protected] writes:

                   
CMA Action Alert
People Before Pharmaceutical  Profits
_Info by Topic_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=OeDFOhtZWSuz7YEUlZuGgsDUq3nx3d6A) 
 _Articles & Alerts_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=fzG32OLczVBGqYmIqQOi6sDUq3nx3d6A) 
 _Litigation_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=DVqzAQFkTtTiCdin5CujFcDUq3nx3d6A) 
 _Take 
Action_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=ULoYT+n7EIsxasVRsot9WCZp0U0fPlgZ) 
 _Donate_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=ZasgDTYqMeQnmbRYAKkRUsDUq3nx3d6A) 
 _Newsroom_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=1wFRbgGEkFjn5NXwzgnBwCZp0U0fPlgZ) 
 _About_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=ZDOHKYNsR7B25u5uzyNpLMDUq3nx3d6A) 
       
Dear Kathy, 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=qT24fZiGE6MQ2J44dnyuiyZp0U0fPlgZ) 
 
On April 16, 2013, the  Medicare Drug Savings Act of 2013, was introduced 
by  Senator Rockefeller of West  Virginia. The Act would allow Medicare to 
strengthen its  muscle by asking the pharmaceutical Industry to provide  
Medicare with reduced pricing on prescription drugs. I  support _this 
commonsense 
 approach_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=hvaEojKhrD54O8axsxq+cMDUq3nx3d6A) 
 along with nearly 70%  of Americans, across party  lines.  
_Tell your Senators that you  support this sensible proposal,  too_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=QiCjeWDeOIT5Kei2QsoeTMDUq3nx3d6A) 
 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=YhdFxxOfcLkPAq0487xWE8DUq3nx3d6A)
 .   

At a time when  Congress and other policymakers consider making drastic 
cuts  to Medicare, supposedly to save money, this legislation is a  real step 
forward that would save $141 billion over ten  years. These savings would end 
sweetheart deals that  brand-name drug companies have had since Congress 
created  Part D in 2006.  
It’s a matter of  priorities. The Medicare Drug Savings Act protects  
beneficiaries and strengthens Medicare for future  generations, rather than 
spending public dollars on profits  for private drug companies.  
Today,   
(http://org.salsalabs.com/dia/track.jsp?v=2&c=BX3tupT1dyATDatFicUuEsDUq3nx3d6A) 
_contact your  Senators_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=hczcDIqpuC8uheruj8Qq+MDUq3nx3d6A) 
 and tell them to  support the 
Medicare Drug Savings Act. Tell them to put  People before Profits.  

Sincerely,

Judith Stein
 
____________________________________
You may _remove your address  from our mailing lists_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=X7BR9DhRq66u/zLMJjR4DsDUq3nx3d6A) 
 at any time. If 
you  would like an address corrected, or would like to add an  address, 
please contact _Matthew  Shepard_ 
(mailto:[email protected]?subject=News Alert) . If you  would like 
to receive a text-only version of this 
alert,  please reply to this message with the subject "text only".   
Matthew E. Shepard
Communications  Coordinator
Center for Medicare Advocacy, Inc.
PO Box  350
Willimantic, CT 06226
[email protected]_ 
(mailto:[email protected]?subject=News Alert)  
(860) 456-7790  (860) 456-2614 (fax)
_www.medicareadvocacy.org_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=98bET+A4gOzLtAei9w5V88DUq3nx3d6A) 
 
The information in this electronic communication is  intended only for the 
use of the individual(s) or entity  named above, and may be legally 
privileged and confidential  under applicable law. If the recipient of this 
message 
is  not the above-named intended recipient(s), you are hereby  notified that 
any dissemination, copy or disclosure of this  communication is strictly 
prohibited. If you have received  this communication in error, please notify 
the sender above  and purge the communication immediately without making any  
copy or  distribution.    Copyright © The Center for Medicare Advocacy, 
Inc.  _www.medicareadvocacy.org_ 
(http://org.salsalabs.com/dia/track.jsp?v=2&c=dbWdzK01am1xeXFPCLgMeMDUq3nx3d6A) 
    
 (http://www.salsalabs.com/?email) 

Reply via email to